ArticleMolecular cancer2019
Lung adenocarcinoma-intrinsic GBE1 signaling inhibits anti-tumor immunity.
Article in Molecular cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 81 citations in OpenAlex.
- Vinburnine Sensitizes Radiotherapy Efficacy in Nasopharyngeal Carcinoma by Triggering Pyroptosis and Immune Responses via Activation of EDAR-NFκB Pathway.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- A lactate related signature for predicting prognosis and tumor microenvironment in lung adenocarcinoma.Discover oncology · 2025Article
- Exploring the relationship between hypoxia in lung adenocarcinoma and tumor microenvironment immune cell infiltration.Discover oncology · 2025Article
- Unveiling GBE1 as a hypoxia-related prognostic gene with significant impact on immune cell infiltration in HER2-enriched breast cancer.Discover oncology · 2025Article
- Hepatic Growth Factor as a Potential Biomarker for Lung Adenocarcinoma: A Multimodal Study.Current issues in molecular biology · 2025Article
- Deep learning analysis of histopathological images predicts immunotherapy prognosis and reveals tumour microenvironment features in non-small cell lung cancer.British journal of cancer · 2024Article
- Necroptosis-related lncRNAs: biomarkers for predicting prognosis and immune response in lung adenocarcinoma.Translational lung cancer research · 2024Article
- WTAP/IGF2BP3-mediated GBE1 expression accelerates the proliferation and enhances stemness in pancreatic cancer cells via upregulating c-Myc.Cellular & molecular biology letters · 2024Article
- The BCL-2 inhibitor APG-2575 resets tumor-associated macrophages toward the M1 phenotype, promoting a favorable response to anti-PD-1 therapy via NLRP3 activation.Cellular & molecular immunology · 2024Article
- Systematic Multiomic Analysis ofInternational journal of molecular sciences · 2023Article
- IL-33/ST2 antagonizes STING signal transduction via autophagy in response to acetaminophen-mediated toxicological immunity.Cell communication and signaling : CCS · 2023Article
- Article
- Article
- Correlation of tumor mutational burden with prognosis and immune infiltration in lung adenocarcinoma.Frontiers in oncology · 2023Article
- cGAS-STING Pathway as the Target of Immunotherapy for Lung Cancer.Current cancer drug targets · 2023Review
- Gene Coexpression Network Characterizing Microenvironmental Heterogeneity and Intercellular Communication in Pancreatic Ductal Adenocarcinoma: Implications of Prognostic Significance and Therapeutic Target.Frontiers in oncology · 2022Article
- Development and Validation of a Combined Hypoxia and Immune Prognostic Classifier for Lung Adenocarcinoma.Journal of Cancer · 2022Article
- A robust CD8Frontiers in immunology · 2022Article
- Study of Single Nucleotide Polymorphisms Associated with Breast Cancer Patients among Arab Ancestries.International journal of breast cancer · 2022Article
- A promising research direction for colorectal cancer immunotherapy: The regulatory mechanism of CCL5 in colorectal cancer.Frontiers in oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChanges in glycogen metabolism is an essential feature among the various metabolic adaptations used by cancer cells to adjust to the conditions imposed by the tumor microenvironment. Our previous study showed that glycogen branching enzyme (GBE1) is downstream of the HIF1 pathway in hypoxia-conditioned lung cancer cells. In the present study, we investigated whether GBE1 is involved in the immune regulation of the tumor microenvironment in lung adenocarcinoma (LUAD).
methodsWe used RNA-sequencing analysis and the multiplex assay to determine changes in GBE1 knockdown cells. The role of GBE1 in LUAD was evaluated both in vitro and in vivo.
resultsGBE1 knockdown increased the expression of chemokines CCL5 and CXCL10 in A549 cells. CD8 expression correlated positively with CCL5 and CXCL10 expression in LUAD. The supernatants from the GBE1 knockdown cells increased recruitment of CD8
conclusionsGBE1 blockade promotes the secretion of CCL5 and CXCL10 to recruit CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.